Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open extension study evaluating the long term efficacy, safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed the previous ziprasidone study A1281031.

Next Previous
X
Search
Trial Profile

Open extension study evaluating the long term efficacy, safety and tolerability of oral ziprasidone in the treatment of patients who have successfully completed the previous ziprasidone study A1281031.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Pfizer; Viatris

    • Most Recent Events

    • 22 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top